FRI0559 ASSOCIATION BETWEEN DIET QUALITY IN CHILDHOOD AND ADULTHOOD AND KNEE SYMPTOMS IN YOUNG ADULTS

Background: The ASAS-EULAR recommendations for management of axial Spondyloarthritis (axSpA) includes that patients should be encouraged to exercise.1 So far, there is no validated instrument for measuring daily physical activity in axSpA. Our previous study recommends to adapt the Short QUestionnaire to Assess Health-enhancing physical activity (SQUASH) to improve the validity in axSpA patients.2 Objectives: AxSpA-disease specific adaptation of the physical activity questionnaire SQUASH to improve content validity and measurement properties. Methods: This study was conducted according to the OMERACT-filter within the Groningen Leeuwarden AxSpA (GLAS) cohort and was performed in two parts. Part 1: adaptation and evaluation of content validity using a qualitative stepwise approach with in-depth interviews with different healthcare professionals (n=9) and patients (n=8), field testing in patients (n=10), and consensus meeting for final adaptations. Thereafter, content validity (n=45) was tested by filling out axSpA-SQUASH and SQUASH in random order two weeks apart. Part 2: measurement properties were tested using the International Physical Activity Questionnaire (IPAQ) as comparator. Criterion validity (n=40): Spearman’s correlation with accelerometer as golden standard and classification accuracy of intensity. Construct validity (n=106): Spearman’s correlation with disease activity, physical functioning and quality of life as clinical outcome with expected fair to moderated associations. Test-retest reliability (n=45): intraclass correlation coefficients (ICC) after 2 weeks. Responsiveness (n=47): standardized response mean (SRM) after 3 months stratified by Ancor method. Results: In total 156 patients were included: mean age 48±13 years, 56% males, 72% HLA-B27 positive, symptom duration 21±13.3 years and ASDAS 2.0±1.0. Part 1: main adaptations were better explanation of intensities, adding answer option “not applicable”, examples were modernized, physiotherapy and activity “shopping” were added. Compared to the original SQUASH, the adapted axSpA-SQUASH measured a systematically higher activity count and had less missing values (8% vs. 32%). Part 2: criterion validity: axSpA-SQUASH correlated better with accelerometer compared to IPAQ (ρ=0.51 vs. ρ=0.35). Classification accuracy: accelerometer defined most activity as light (97%), whereas axSpA-SQUASH and IPAQ defined most activity as moderate intensity (55% and 62% resp.). Construct validity: correlations were low to moderate and strongest for axSpA-SQUASH compared to IPAQ. Construct validity: correlations were low to moderate and stronger for axSpA-SQUASH compared to IPAQ (BASDAI -0.27 vs -0.15, BASDAI –0.27 vs. -0.15, ASDAS -0.24 vs -0.09, BASFI -0.39vs. -0.21, ASQoL -0.39 vs. -0.35). Test-retest reliability: ICC axSpA-SQUASH: 0.80. Responsiveness: axSpA-SQUASH changed over time in the corresponding direction (Table 1). Feasibility: considered comprehensible and average completion time was 7 minutes. Conclusion: The new axSpA-SQUASH resulted in improved content validity and measurement properties. It seems the most appropriate questionnaire and can be used to assess daily physical activity in patients with axSpA. References: [1] Van Der Heijde D et al. Ann Rheum Dis. 2017;76:978-91. [2] Arends S et al. Arthritis Res Ther. 2013;15:R99. Acknowledgments: We thank the ASAS for the reserch grant that supported this work. Disclosure of Interests: Marlies Carbo: None declared, Davy Paap: None declared, Fiona Maas: None declared, Anna Jetske Baron: None declared, Laura van Overbeeke: None declared, Mark Siderius: None declared, Freke Wink Consultant of: Abbvie, Janssen, Hendrika Bootsma Grant/research support from: Unrestricted grants from Bristol-Myers Squibb and Roche, Consultant of: Consultant for Bristol-Myers Squibb, Roche, Novartis, Medimmune, Union Chimique Belge, Speakers bureau: Speaker for Bristol-Myers Squibb and Novartis., Suzanne Arends Grant/research support from: Grant/research support from Pfizer, Anneke Spoorenberg: None declared